The development and approval of immune checkpoint (programmed cell death protein 1 [PD-1], programmed cell death-ligand 1 [PD-L1], and cytotoxic T-lymphocyte associated protein 4 [CTLA4]) inhibitors leaded to dramatic changes in the landscape of cancer therapy (Robert, 2020). This evidence concerns the gene CD274 and cancer.